

EFA PATIENTS' DIGITAL PRIZE 2023

Terms of Reference for Applicants



European Federation of Allergy and Airways
Diseases Patients' Associations

DIG_IT Prize

EFA Patients' Digital Prize 2023

Terms of reference for applicants

INTRODUCTION

The European Federation of Allergy and Airways Diseases Patients' Associations (EFA) is an independent non-profit organisation with its central office located in Brussels, Belgium. EFA connects 45 allergy, asthma, and chronic obstructive pulmonary disease (COPD) patients' associations in 26 countries.

In the first half of 2023, EFA will be granting a Patient's Digital Prize to reward patient-centred, digital health initiatives that centre patients through their design, accessibility, and efficacy.

BACKGROUND

In 2020 EFA launched the Digital Information Technology (DIG_IT) Project, which aimed at bringing asthma and COPD patients to the heart of the digital solutions they use. The project included a patient survey conducted in five different European countries and involving 970 patients. The results have been published in **2022 DIG_IT Report: Asthma and COPD patients' digital journey in Europe** (<https://efanet.org/inform/patient-evidence/dig-it>).

The EFA's DIG_IT Project, survey and survey report have been funded with unrestricted grants from EFA's Sustainable Corporate Partners Astra Zeneca, Chiesi, MSD, OM Pharma and Roche. The EFA's DIG_IT Prize is being made possible thanks to unrestricted grants from EFA's Sustainable Corporate Partners Chiesi and Roche.

SCOPE

The prize will be granted to digital health technologies. The prize aims to mark the recognition of a creator and/or a developer of a technology or system as a good solution for asthma and COPD patient-centred digital health care.

The **EFA Patients' Digital Prize** will acknowledge digital technologies that fit in one of three disease-focused categories:

- Prize for best digital technology covering asthma.
- Prize for best digital technology covering COPD.
- Prize for best digital technology covering both asthma & COPD.

AGREEMENT TO TERMS

By entering the **EFA Patients' Digital Prize** competition, you confirm that you have read, understood, and agree to be bound by the terms of reference and rules of the competition.

Supplemental terms and conditions or documents outlining guidelines in relation to the **EFA Patients' Digital Prize** are incorporated herein by reference. EFA reserves the right, at its sole discretion, to make changes and modifications to these terms and conditions. Any changes that update these terms will be indicated at the end of this document by the 'Last Updated' date. By agreeing to these terms and conditions, you waive any right to receive specific notice of each such change. All changes will be applied from the moment at which they have been updated and published online.

TIMELINE OF THE COMPETITION

The **EFA Patients' Digital Prize** has the following timeline:

- **Call for submissions:** 1 February 2023 – Monday 27, March 2023 (eight weeks)
- **Selection of the Jury:** March 27, 2023
- **Evaluation period:** March 28, 2023 – April 2, 2023
- **Announcement of finalists:** April 10, 2023
- **Prize ceremony:** 27-28 April 2023 in Ghent, Belgium

ENTRY TO THE COMPETITION

To enter the **EFA Patients' Digital Prize**, all applicants are required to complete in full and submit the EFA Patients' Digital Prize form and send it to EFA by Monday, 27 March 2023, 17:00 CET.

When completing the submission form, participants are required to choose among the three main prize categories: asthma, COPD, or both diseases. The submission should be made to the category which best fits the digital technology. While the first two categories focus on digital technologies that have as their scope exclusively just one of the two diseases, the third category applies to digital technologies that have both diseases in their scope.

Multiple submissions by the same applicant are allowed. However, should the technology submitted cover both disease areas, it cannot additionally be entered into the competition under either of the two categories covering the individual disease areas. (i.e., an app which has within its scope both asthma and COPD, must be entered into the third category only. Wrong submissions will not be taken into account for the competition.

METHODS OF EVALUATION

To choose the winners of each category, a jury panel of eight individuals will be selected by the EFA Secretariat by March 2023 that is composed of:

- 1 asthma patients' representative from EFA Members
- 1 COPD patients' representative from EFA Members
- 1 young asthma patient from the European Allergy & Asthma Youth Parliament
- 1 healthcare professional from the respiratory sector
- 1 digital health industry expert
- 1 payer representative
- 1 European/EU Digital Health Authority representative
- 1 representative from the EFA Sustainable Corporate Partners (pharma) that support the EFA DIG_IT project with unrestricted grants.

The jury members will be announced via the appropriate EFA communication channels (e.g. website, social media) before the deadline for submissions has passed.

The assessment will be done by all the jury members following the principles of fairness, transparency, and independence throughout the process of evaluation, according to the prize evaluation grid (available on EFA website) and taking into account the evaluation criteria as set out for the purpose of the **EFA Patients' Digital Prize**. There are six main

criteria on which the jury members will base their evaluation: accessibility, partnership with healthcare professionals, convenience, support and security, prevention, and equity. For each criterion, submissions will receive a maximum of 5 points, amounting to a maximum total of 70 points. Following the careful evaluation of all submissions, the prize winner(s) will be selected.

The announcement of the prize winner(s) for each category will be made via EFA media channels on April 4th 2023. The finalists will be invited to the award ceremony late April 2023 in presence of EFA's 45 patients' organisations in 26 countries, to benefit from structured exchanges with the asthma and COPD patient community in Europe.

WITHDRAWAL & AMENDMENTS

An applicant has the right to withdraw from the competition without giving any reason or without any consequences. Should an applicant choose to withdraw its submission from the competition, it shall do so by March 28th, 2023, by giving notice in writing to EFA stating its decision to withdraw. Such notice shall be unconditional and irrevocable when given.

In the event an applicant wishes to modify its submission, it should do so within the deadline of submission of the application for the prize. Any modifications to the submission will not be considered after the deadline to apply has passed.

COMMUNICATION & SOCIAL MEDIA

By taking part in the **EFA Patients' Digital Prize**, an applicant consents to receiving electronic communications from EFA in relation to any issues related to the EFA Digital Patients' Prize, such as, but not limited to, the selection process, request for additional information, and information about the prize ceremony.

Applicants will be requested either to provide and/or partake in various promotional materials during the prize process, including supply of a short bio and photo to be included on the EFA Patients' Digital Prize website. Throughout and after the competition, applicants may be requested to participate in short promotional videos and have their

submissions promoted via social media channels. By taking part in the EFA Patients' Digital Prize, applicants consent to having this information made public, unless explicitly requested otherwise by contacting in writing the EFA Secretariat.

Disclaimer

The **EFA Patients' Digital Prize** acts purely as a recognition and acknowledgement of digital developments in health which put patients at the heart of digital solutions. The EFA Patients' Digital Prize does not certify in any form whatsoever the use of an end product that arises from the submission(s). The prize applies only to the digital technology as submitted by the applicant, and not to any subsequent developments of that digital technology. As such, EFA does not take any responsibility for, nor does it recognise any of the further developments of, the submission beyond what has been submitted for the prize consideration.

Privacy Policy

By entering in the **EFA Patients' Digital Prize** as an applicant, the general Privacy Policy (<https://efanet.org/privacy-policy>) of EFA will automatically be applied and complied with.

Intellectual Property Rights

EFA holds all the intellectual property rights related to the EFA Patients' Digital Prize, including its concept and organisation. Any intellectual property rights of the submissions are owned by the respective applicants.

Limitations of Liability

In the absence of negligence, bad faith, or wilful misconduct, EFA shall not be liable to any applicant or jury member, or any other person, including any party claiming by, through or on behalf of the applicants or jury members, for any losses, liabilities, damages, costs, or expenses arising out of an error in data or other information provided to them. EFA does not take any responsibility for any losses, liabilities, damages, costs, or expenses arising out of the use of the digital health technology and/or systems submitted for consideration within the EFA Patients' Digital Prize, nor any subsequent developments of the submissions to the prize.

Contact Details

European Federation of Allergy and Airways Diseases Patients Associations
35 Rue du Congrès, 1000 Brussels, Belgium

projects@efanet.org

+32(0)2 227 27 12

EU Transparency Register Identification Number: 28473847513-94

Participants are also able to ask us to correct any mistakes in the information we hold on them or ask for the data to be deleted (assuming that EFA has no other obligation to keep the data; we would encourage jury members to let us use it for suppression purposes only).

Last updated on 31/01/2023

